The efficacy and safety of Yadanzi oil injection in the treatment of advanced colon cancer

Shanxi Province Hospital of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Age 18-80, no gender limitation;
•2. Patients with tumor whose clinical stage was stage IV and could not be radically resected.
•3. No previous chemotherapy;
•4. Quality of Life Score (KPS Score) =60;
•5. The expected survival time is more than 6 months;
•6. Good compliance; informed consent was signed before enrollment;
•7. Patients agree not to participate in other intervention studies during treatment.

•1. Those with specific targeted therapy through genetic testing;
•2. Patients with other primary malignant tumors;
•3. Patients with serious complications of cardiovascular system, cerebrovascular system, active hepatitis, and serious liver and kidney dysfunction that can't tolerate chemotherapy;
•4. Patients with severe bleeding tendency who cannot use bevacizumab;
•5. Those who have received first-line chemotherapy or above;
•6. Patients receiving other immunotherapy;
•7. Allergic to the test drug;
•8. Women during lactation and pregnancy;
•9. Those who cannot comply with the requirements of the scheme or experiment;
•10. People with severe mental illness, bad fluid, and can't cooperate with treatment;
•11. Used other Proprietary Chinese medicines with anti-tumor and improved immunity.

发起方

Shanxi Province Hospital of Traditional Chinese Medicine